Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25788066 | 1.00 | ALDH1A1 (0.84) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL1505142 | 0.95 | ALDH1A1 (0.74) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL26355092 | 0.94 | ALDH1A1 (0.73) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL24801375 | 0.92 | ALDH1A1 (1.00) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL14964190 | 0.92 | ALDH1A1 (1.00) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL8945690 | 0.89 | ALDH1A1 (0.66) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL6043026 | 0.89 | ALDH1A1 (0.76) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL29013661 | 0.87 | ALDH1A1 (0.84) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL3383338 | 0.87 | ALDH1A1 (0.67) | ALDH1A1KMT2APTK2BKDM4ELMNA | |
| SCHEMBL6044048 | 0.87 | ALDH1A1 (0.67) | ALDH1A1KMT2APTK2BKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233964-A | Single component delivery system for nucleic acids | 宾夕法尼亚大学理事会 | 2024-12-31 | — | — | CN | disclosed |
| CN-114466835-B | Thermally responsive molecules for controlled heat and light transmission windows and uses thereof | 科学与工业研究会 | 2024-06-04 | — | — | CN | disclosed |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| CN-114466835-A | Thermally responsive molecules for controlled thermal and optical transmission windows and uses thereof | 科学与工业研究会 | 2022-05-10 | — | — | CN | disclosed |
| CN-108558701-B | Micromolecule AIEE luminescent material with triple stimulus responsiveness and preparation method thereof | 湘潭大学 | 2020-11-03 | — | — | CN | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5925780-A | VIRICIDES FOR RETROVIRAL SPECIES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-07-20 | — | — | US | disclosed |
| US-5728718-A | RETROVIRAL PROTEASE INHIBITOR; TREATMENT OF HTLV | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-03-17 | — | — | US | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SLC6A9, SLC6A5, REN | ALDH1A1 3949/4885KMT2A 2175/4885PTK2B 2390/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | ALDH1A1 1039/4885KMT2A 2309/4885PTK2B 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.